Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 466

1.

Economic Analysis of Adjuvant Chemoradiotherapy Compared with Chemotherapy in Resected Pancreas Cancer.

Vela N, Davis LE, Cheng SY, Hammad A, Liu Y, Kagedan DJ, Paszat L, Bubis LD, Earle CC, Myrehaug S, Mahar AL, Mittmann N, Coburn NG; Pancreas Cancer Population Outcomes Research Group.

Ann Surg Oncol. 2019 Sep 18. doi: 10.1245/s10434-019-07808-8. [Epub ahead of print]

PMID:
31535303
2.

Histone Modifications as Biomarkers for Immunotherapy.

Taylor EM, Koss B, Davis LE, Tackett AJ.

Methods Mol Biol. 2020;2055:213-228. doi: 10.1007/978-1-4939-9773-2_10.

PMID:
31502154
3.

Population-Level Symptom Assessment Following Pancreaticoduodenectomy for Adenocarcinoma.

Tung S, Davis LE, Hallet J, Mavros MN, Mahar AL, Bubis LD, Hammad A, Zhao H, Earle CC, Barbera L, Coburn NG; and the Pancreas Cancer Population Outcomes Research Group, Siqqidui M, Li Q, Elmi M, Shin E, Hsieh E, Goyert N.

JAMA Surg. 2019 Sep 4:e193348. doi: 10.1001/jamasurg.2019.3348. [Epub ahead of print]

PMID:
31483457
4.

Effect of intermittent versus continuous low dose aspirin on nasal epithelium gene expression in current smokers: A randomized, double-blinded trial.

Garland L, Guillen-Rodriguez J, Hsu CH, Yozwiak M, Zhang HH, Alberts DS, Davis LE, Szabo E, Merenstein C, Lel J, Zhang X, Liu H, Liu G, Spira AE, Beane J, Wojtowicz M, Chow HS.

Cancer Prev Res (Phila). 2019 Aug 26. pii: canprevres.0036.2019. doi: 10.1158/1940-6207.CAPR-19-0036. [Epub ahead of print]

PMID:
31451521
5.

Patient-reported symptom severity among 22,650 cancer outpatients in the last 6 months of life.

Bubis LD, Davis LE, Canaj H, Gupta V, Jeong Y, Barbera L, Li Q, Moody L, Karanicolas PJ, Sutradhar R, Coburn NG, Mahar AL.

J Pain Symptom Manage. 2019 Aug 17. pii: S0885-3924(19)30462-2. doi: 10.1016/j.jpainsymman.2019.08.016. [Epub ahead of print]

PMID:
31430522
6.

PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor.

Davis LE, Nicholls LA, Babiker HM, Liau J, Mahadevan D.

Cancer Immunol Res. 2019 Sep;7(9):1396-1400. doi: 10.1158/2326-6066.CIR-19-0072. Epub 2019 Aug 5.

PMID:
31383651
7.

Current state of melanoma diagnosis and treatment.

Davis LE, Shalin SC, Tackett AJ.

Cancer Biol Ther. 2019 Aug 1:1-14. doi: 10.1080/15384047.2019.1640032. [Epub ahead of print]

PMID:
31366280
8.

Symptom trajectories and predictors of severe symptoms in pancreatic adenocarcinoma at the end-of-life: a population based analysis of 2,538 patients.

Hammad A, Davis LE, Mahar AL, Bubis LD, Zhao H, Earle CC, Barbera L, Hallet J, Coburn NG.

HPB (Oxford). 2019 Jul 9. pii: S1365-182X(19)30537-4. doi: 10.1016/j.hpb.2019.04.016. [Epub ahead of print]

PMID:
31300337
9.

Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes.

Hallet J, Davis LE, Mahar AL, Law CHL, Isenberg-Grzeda E, Bubis LD, Singh S, Myrehaug S, Zhao H, Beyfuss K, Moody L, Coburn NG.

Oncologist. 2019 Jul 3. pii: theoncologist.2019-0112. doi: 10.1634/theoncologist.2019-0112. [Epub ahead of print]

PMID:
31270268
10.

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.

Berlow NE, Rikhi R, Geltzeiler M, Abraham J, Svalina MN, Davis LE, Wise E, Mancini M, Noujaim J, Mansoor A, Quist MJ, Matlock KL, Goros MW, Hernandez BS, Doung YC, Thway K, Tsukahara T, Nishio J, Huang ET, Airhart S, Bult CJ, Gandour-Edwards R, Maki RG, Jones RL, Michalek JE, Milovancev M, Ghosh S, Pal R, Keller C.

BMC Cancer. 2019 Jun 17;19(1):593. doi: 10.1186/s12885-019-5681-6.

11.

Leg Length Discrepancy: The Natural History (And What Do We Really Know).

Gordon JE, Davis LE.

J Pediatr Orthop. 2019 Jul;39(Issue 6, Supplement 1 Suppl 1):S10-S13. doi: 10.1097/BPO.0000000000001396. Review.

PMID:
31169640
12.

Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes.

Hallet J, Davis LE, Mahar AL, Isenberg-Grzeda E, Bubis LD, Myrehaug S, Zhao H, Beyfuss K, Moody L, Law CHL, Coburn NG.

Ann Surg Oncol. 2019 Sep;26(9):2711-2721. doi: 10.1245/s10434-019-07441-5. Epub 2019 May 30.

PMID:
31147993
13.

Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis.

Mavros MN, Coburn NG, Davis LE, Mahar AL, Liu Y, Beyfuss K, Myrehaug S, Earle CC, Hallet J.

CMAJ. 2019 May 27;191(21):E574-E580. doi: 10.1503/cmaj.190211.

14.

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG.

J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23.

PMID:
31013172
15.

Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.

Davis LE, Fulton C, Bubis LD, Sussman J, Moody L, Barbera L, Li Q, Mahar AL, Coburn NG, Holloway CMB.

Breast Cancer Res Treat. 2019 Jun;175(3):721-731. doi: 10.1007/s10549-019-05196-x. Epub 2019 Mar 16.

PMID:
30879223
16.

Factors associated with receipt of symptom screening in the year after cancer diagnosis in a universal health care system: a retrospective cohort study.

Mahar AL, Davis LE, Bubis LD, Li Q, Sutradhar R, Coburn NG, Barbera L.

Curr Oncol. 2019 Feb;26(1):e8-e16. doi: 10.3747/co.26.4160. Epub 2019 Feb 1.

17.

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.

Haas NB, Appleman LJ, Stein M, Redlinger M, Wilks M, Xu X, Onorati A, Kalavacharla A, Kim T, Zhen CJ, Kadri S, Segal JP, Gimotty PA, Davis LE, Amaravadi RK.

Clin Cancer Res. 2019 Apr 1;25(7):2080-2087. doi: 10.1158/1078-0432.CCR-18-2204. Epub 2019 Jan 11.

PMID:
30635337
18.

Safety and efficacy of high-dose methotrexate for osteosarcoma in adolescents compared with young adults.

Wippel B, Gundle KR, Dang T, Paxton J, Bubalo J, Stork L, Fu R, Ryan CW, Davis LE.

Cancer Med. 2019 Jan;8(1):111-116. doi: 10.1002/cam4.1898. Epub 2018 Dec 22.

19.

Foramen ovale blood flow and cardiac function after main pulmonary artery occlusion in fetal sheep.

Lantto J, Erkinaro T, Haapsamo M, Huhta H, Voipio HM, Hohimer AR, Davis LE, Acharya G, Räsänen J.

Exp Physiol. 2019 Feb;104(2):189-198. doi: 10.1113/EP087423. Epub 2019 Jan 13.

PMID:
30578690
20.

Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.

Davis LE, Nusser KD, Przybyl J, Pittsenbarger J, Hofmann NE, Varma S, Vennam S, Debiec-Rychter M, van de Rijn M, Davare MA.

Mol Cancer Res. 2019 Mar;17(3):676-685. doi: 10.1158/1541-7786.MCR-18-1075. Epub 2018 Dec 5. Erratum in: Mol Cancer Res. 2019 Sep;17(9):1958.

PMID:
30518629
21.

Dynamin Is Required for Efficient Cytomegalovirus Maturation and Envelopment.

Hasan MH, Davis LE, Bollavarapu RK, Mitra D, Parmar R, Tandon R.

J Virol. 2018 Nov 27;92(24). pii: e01418-18. doi: 10.1128/JVI.01418-18. Print 2018 Dec 15.

22.

Acute Bacterial Meningitis.

Davis LE.

Continuum (Minneap Minn). 2018 Oct;24(5, Neuroinfectious Disease):1264-1283. doi: 10.1212/CON.0000000000000660.

PMID:
30273239
23.
24.

Using Teleneurology to Deliver Chronic Neurologic Care to Rural Veterans: Analysis of the First 1,100 Patient Visits.

Davis LE, Harnar J, LaChey-Barbee LA, Pirio Richardson S, Fraser A, King MK.

Telemed J E Health. 2019 Apr;25(4):274-278. doi: 10.1089/tmj.2018.0067. Epub 2018 Jul 17.

PMID:
30016207
25.

Patient-reported symptoms after breast cancer diagnosis and treatment: A retrospective cohort study.

Davis LE, Bubis LD, Mahar AL, Li Q, Sussman J, Moody L, Barbera L, Holloway CM, Coburn NG.

Eur J Cancer. 2018 Sep;101:1-11. doi: 10.1016/j.ejca.2018.06.006. Epub 2018 Jul 13.

PMID:
30014970
26.

Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment.

Vander Jagt TA, Davis LE, Thakur MD, Franz C, Pollock JM.

Radiol Case Rep. 2018 Jul 3;13(4):882-885. doi: 10.1016/j.radcr.2018.05.013. eCollection 2018 Aug.

27.

Combined angiotensin receptor and neprilysin inhibition therapy for heart failure.

Lu BN, Davis LE.

JAAPA. 2018 Jul;31(7):35-37. doi: 10.1097/01.JAA.0000534982.53989.c2.

PMID:
29957605
28.

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A.

Cancer Cell. 2018 Jul 9;34(1):9-20. doi: 10.1016/j.ccell.2018.03.023. Epub 2018 May 3. Review.

29.

A Pilot Study on an Interprofessional Course Involving Pharmacy and Dental Students in a Dental Clinic.

Pogge EK, Hunt RJ, Patton LR, Reynolds SC, Davis LE, Storjohann TD, Tennant SE, Call SR.

Am J Pharm Educ. 2018 Apr;82(3):6361. doi: 10.5688/ajpe6361.

30.

A Case of Self-Enucleation in an Incarcerated Patient: Case Report and Review of Literature.

Davis LE, Tripathi S.

J Forensic Sci. 2018 Nov;63(6):1908-1910. doi: 10.1111/1556-4029.13764. Epub 2018 Feb 21. Review.

PMID:
29464687
31.

Evaluating the Safety and Tolerability of Sacubitril/Valsartan for HFrEF Managed Within a Pharmacist Clinic.

Pogge EK, Davis LE.

Am J Cardiovasc Drugs. 2018 Apr;18(2):143-151. doi: 10.1007/s40256-018-0264-5.

PMID:
29455335
32.

Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas.

Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW.

Ann Surg Oncol. 2018 Apr;25(4):920-927. doi: 10.1245/s10434-018-6346-4. Epub 2018 Jan 31.

PMID:
29388122
33.

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling?

Fairman KA, Davis LE, Peckham AM, Sclar DA.

Drugs Real World Outcomes. 2018 Mar;5(1):69-79. doi: 10.1007/s40801-017-0129-2.

34.

The Diuretic Potential of Sacubitril/Valsartan: A Tale of 2 Patients.

Hormann SM, Davis LE, Pogge EK.

J Cardiovasc Nurs. 2018 Mar/Apr;33(2):104-110. doi: 10.1097/JCN.0000000000000451.

PMID:
29232274
35.

Osteosarcoma, Chondrosarcoma, and Chordoma.

Whelan JS, Davis LE.

J Clin Oncol. 2018 Jan 10;36(2):188-193. doi: 10.1200/JCO.2017.75.1743. Epub 2017 Dec 8. Review.

PMID:
29220289
36.

Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species.

Davis LE, Jeng S, Svalina MN, Huang E, Pittsenbarger J, Cantor EL, Berlow N, Seguin B, Mansoor A, McWeeney SK, Keller C.

Oncotarget. 2017 Jul 25;8(44):76241-76256. doi: 10.18632/oncotarget.19532. eCollection 2017 Sep 29.

37.

Fetal sheep central haemodynamics and cardiac function during occlusion of the ascending aorta.

Huhta H, Junno J, Haapsamo M, Erkinaro T, Ohtonen P, Davis LE, Hohimer AR, Acharya G, Rasanen J.

Exp Physiol. 2018 Jan 1;103(1):58-67. doi: 10.1113/EP086500. Epub 2017 Dec 3.

PMID:
29094424
38.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba II, Baker LH, Maki RG, Reinke D, Patel S.

Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. Epub 2017 Oct 4. Erratum in: Lancet Oncol. 2017 Dec;18(12 ):e711. Erratum in: Lancet Oncol. 2018 Jan;19(1):e8.

PMID:
28988646
39.

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice.

Fairman KA, Davis LE, Sclar DA.

Ther Clin Risk Manag. 2017 Aug 3;13:957-965. doi: 10.2147/TCRM.S143008. eCollection 2017.

40.

Clinical trial enrollment of adolescents and young adults with sarcoma.

Davis LE, Janeway KA, Weiss AR, Chen YE, Scharschmidt TJ, Krailo M, Glade Bender JL, Kopp LM, Patel SR, Schwartz GK, Horvath LE, Hawkins DS, Chuk MK, Reinke DK, Gorlick RG, Randall RL.

Cancer. 2017 Sep 15;123(18):3434-3440. doi: 10.1002/cncr.30757. Epub 2017 May 11. Review.

41.

Inhibition of endocytic pathways impacts cytomegalovirus maturation.

Archer MA, Brechtel TM, Davis LE, Parmar RC, Hasan MH, Tandon R.

Sci Rep. 2017 Apr 13;7:46069. doi: 10.1038/srep46069.

42.

Authorities and Mechanisms for Purchased Care at the Department of Veterans Affairs.

Greenberg MD, Batka C, Buttorff C, Dunigan M, Lovejoy SL, McGovern G, Pace NM, Pillemer F, Williams KM, Apaydin E, Aranibar C, Buenaventura M, Carter P, Cherney S, Davis LE, Donohue AG, Geyer L, Hemler J, Roshan P, Skrabala L, Simmons S, Thompson J, Welch J, Hosek SD, Farmer CM.

Rand Health Q. 2016 May 9;5(4):15. eCollection 2016 May 9.

43.

Financial Impact of Direct-Acting Oral Anticoagulants in Medicaid: Budgetary Assessment Based on Number Needed to Treat.

Fairman KA, Davis LE, Kruse CR, Sclar DA.

Appl Health Econ Health Policy. 2017 Apr;15(2):203-214. doi: 10.1007/s40258-016-0295-5.

PMID:
27896681
44.

Constructive ways to prevent, identify, and remediate deficiencies of "challenging trainees" in experiential education.

Davis LE, Miller ML, Raub JN, Gortney JS.

Am J Health Syst Pharm. 2016 Jul 1;73(13):996-1009. doi: 10.2146/ajhp150330. Review. No abstract available.

PMID:
27325881
45.

An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction.

Berlow N, Haider S, Wan Q, Geltzeiler M, Davis LE, Keller C, Pal R.

IEEE/ACM Trans Comput Biol Bioinform. 2014 Nov-Dec;11(6):995-1008. doi: 10.1109/TCBB.2014.2321138.

PMID:
26357038
46.

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, Jimeno A, Varella-Garcia M, Aisner DL, Li Y, Stephens PJ, Morosini D, Tuch BB, Fernandes M, Nanda N, Low JA.

Cancer Discov. 2015 Oct;5(10):1049-57. doi: 10.1158/2159-8290.CD-15-0443. Epub 2015 Jul 27.

47.

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.

Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M.

Nat Med. 2015 Jul;21(7):827. doi: 10.1038/nm0715-827a. No abstract available.

PMID:
26151328
48.

Should patients with chronic liver disease receive venous thromboembolism prophylaxis?

Dang JD, Davis LE.

JAAPA. 2015 Jun;28(6):27-8, 30. doi: 10.1097/01.JAA.0000463876.73116.91.

PMID:
25989432
49.

Preoperative therapy for extremity soft tissue sarcomas.

Davis LE, Ryan CW.

Curr Treat Options Oncol. 2015 Jun;16(6):25. doi: 10.1007/s11864-015-0346-4. Review.

PMID:
25975446
50.

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.

Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hütt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M.

Nat Med. 2015 Jun;21(6):555-9. doi: 10.1038/nm.3855. Epub 2015 May 4. Erratum in: Nat Med. 2015 Jul;21(7):827.

Supplemental Content

Loading ...
Support Center